Craddock N, Jones I
Division of Neuroscience, University of Birmingham, Queen Elizabeth Psychiatric Hospital, UK.
J Med Genet. 1999 Aug;36(8):585-94. doi: 10.1136/jmg.36.8.585.
Bipolar disorder (also known as manic depressive illness) is a complex genetic disorder in which the core feature is pathological disturbance in mood (affect) ranging from extreme elation, or mania, to severe depression usually accompanied by disturbances in thinking and behaviour. The lifetime prevalence of 1% is similar in males and females and family, twin, and adoption studies provide robust evidence for a major genetic contribution to risk. There are methodological impediments to precise quantification, but the approximate lifetime risk of bipolar disorder in relatives of a bipolar proband are: monozygotic co-twin 40-70%; first degree relative 5-10%; unrelated person 0.5-1.5%. Occasional families may exist in which a single gene plays the major role in determining susceptibility, but the majority of bipolar disorder involves the interaction of multiple genes (epistasis) or more complex genetic mechanisms (such as dynamic mutation or imprinting). Molecular genetic positional and candidate gene approaches are being used for the genetic dissection of bipolar disorder. No gene has yet been identified but promising findings are emerging. Regions of interest identified in linkage studies include 4p16, 12q23-q24, 16p13, 21q22, and Xq24-q26. Chromosome 18 is also of interest but the findings are confusing with up to three possible regions implicated. To date most candidate gene studies have focused on neurotransmitter systems influenced by medication used in clinical management of the disorder but no robust positive findings have yet emerged. It is, however, almost certain that over the next few years bipolar susceptibility genes will be identified. This will have a major impact on our understanding of disease pathophysiology and will provide important opportunities to investigate the interaction between genetic and environmental factors involved in pathogenesis. This is likely to lead to major improvements in treatment and patient care but will also raise important ethical issues that will need to be addressed.
双相情感障碍(也称为躁郁症)是一种复杂的遗传性疾病,其核心特征是情绪(情感)的病理性紊乱,范围从极度兴奋(即躁狂)到严重抑郁,通常还伴有思维和行为紊乱。男性和女性的终生患病率均为1%,家族、双胞胎和收养研究有力地证明了遗传因素对患病风险有重大影响。精确量化存在方法学上的障碍,但双相情感障碍先证者亲属的终生患病风险大致为:同卵双胞胎40 - 70%;一级亲属5 - 10%;非亲属0.5 - 1.5%。偶尔可能存在单个基因在决定易感性方面起主要作用的家庭,但大多数双相情感障碍涉及多个基因的相互作用(上位性)或更复杂的遗传机制(如动态突变或印记)。分子遗传学定位和候选基因方法正被用于双相情感障碍的基因剖析。尚未确定任何基因,但有一些有希望的发现正在出现。连锁研究中确定的感兴趣区域包括4p16、12q23 - q24、16p13、21q22和Xq24 - q26。18号染色体也受到关注,但研究结果令人困惑,涉及多达三个可能的区域。迄今为止,大多数候选基因研究都集中在受该疾病临床治疗用药影响的神经递质系统上,但尚未出现有力的阳性结果。然而,几乎可以肯定的是,在未来几年内将确定双相情感障碍的易感基因。这将对我们对疾病病理生理学的理解产生重大影响,并为研究发病机制中遗传和环境因素之间的相互作用提供重要机会。这可能会导致治疗和患者护理方面的重大改进,但也会引发需要解决的重要伦理问题。